ClinicalTrials.gg
RecruitingNCT07619118Updated Oct 5, 2026

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

A Phase 3 interventional study of laroprovstat/rosuvastatin 1 and laroprovstat/rosuvastatin 2 in Hypercholesterolaemia, sponsored by AstraZeneca. Recruiting at 45 sites in 4 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 5, 2026Now RecruitingFirst sites in 4 new countries+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies in Hypercholesterolemia by AstraZeneca — 3 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · AstraZeneca.

Planned enrollment
25th of 33
200 · median 840
Started
2026
with 3 others
Phase 3
25 of 60
3 open now
Registered
58th of 60
by date

Among the 60 studies in Hypercholesterolemia by AstraZeneca, this one is the 25th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2026, is one of 25 in phase 3, and was the 58th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 60 studies in Hypercholesterolemia by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Hypercholesterolemia by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect on low-density lipoprotein-cholesterol (LDL-C) and the safety and tolerability of a fixed dose combination (FDC) of laroprovstat/rosuvastatin versus rosuvastatin alone in patients with hypercholesterolaemia with either a history of a clinical atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first clinical ASCVD event.

03

Conditions studied

  • Hypercholesterolaemia

Keywords

  • Hypercholesterolaemia
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age
  • Participants must be on a stable dose of all background LLTs
  • The stable statin dose should be judged as their maximally tolerated dose
  • Participants should have either history of a clinical ASCVD event or be at increased risk for a first clinical ASCVD event

Exclusion criteria

Exclusion Criteria:

  • Asian origin
  • Uncontrolled severe hypertension
  • Uncontrolled T2DM
  • Inadequately treated hypothyroidism
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    laroprovstat/rosuvastatin dose 1

    Patient will receive a daily dose of laroprovstat/rosuvastatin 1 and a placebo to match rosuvastatin 1

    Combination Product: laroprovstat/rosuvastatin 1 · Drug: Placebo to match Rosuvastatin

  • Active comparator
    rosuvastatin dose 1

    Patient will receive a daily dose of rosuvastatin 1 and placebo to match laroprovstat/rosuvastatin 1

    Drug: Placebo to match laroprovstat/rosuvastatin 1,2,3 · Drug: Rosuvastatin 1

  • Experimental
    laroprovstat/rosuvastatin dose 2

    Patient will receive a daily dose of laroprovstat/rosuvastatin 2 and a placebo to match rosuvastatin 2

    Combination Product: laroprovstat/rosuvastatin 2 · Drug: Placebo to match Rosuvastatin

  • Active comparator
    rosuvastatin dose 2

    Patient will receive a daily dose of rosuvastatin 2 and placebo to match laroprovstat/rosuvastatin 2

    Drug: Placebo to match laroprovstat/rosuvastatin 1,2,3 · Drug: Rosuvastatin 2

  • Experimental
    laroprovstat/rosuvastatin dose 3

    Patient will receive a daily dose of laroprovstat/rosuvastatin 3 and a placebo to match rosuvastatin 3

    Combination Product: laroprovstat/rosuvastatin 3 · Drug: Placebo to match Rosuvastatin

  • Active comparator
    rosuvastatin dose 3

    Patient will receive a daily dose of rosuvastatin 3 and placebo to match laroprovstat/rosuvastatin 3

    Drug: Placebo to match laroprovstat/rosuvastatin 1,2,3 · Drug: Rosuvastatin 3

  • Experimental
    laroprovstat/rosuvastatin dose 4

    Patient will receive a daily dose of laroprovstat/rosuvastatin 4 and a placebo to match rosuvastatin 4

    Combination Product: laroprovstat/rosuvastatin 4 · Drug: Placebo to match Rosuvastatin

  • Active comparator
    rosuvastatin dose 4

    Patient will receive a daily dose of rosuvastatin 4 and placebo to match laroprovstat/rosuvastatin 4

    Drug: Placebo to match laroprovstat/rosuvastatin 4 · Drug: Rosuvastatin 4

Interventions

  • Combination productlaroprovstat/rosuvastatin 1

    daily oral dose of the laroprovstat/rosuvastatin 1

  • Combination productlaroprovstat/rosuvastatin 2

    daily oral dose of the laroprovstat/rosuvastatin 2

  • Combination productlaroprovstat/rosuvastatin 3

    daily oral dose of the laroprovstat/rosuvastatin 3

  • Combination productlaroprovstat/rosuvastatin 4

    daily oral dose of the laroprovstat/rosuvastatin 4

  • DrugPlacebo to match laroprovstat/rosuvastatin 1,2,3

    Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 1,2,3

  • DrugPlacebo to match laroprovstat/rosuvastatin 4

    Daily oral dose of placebo to match FDC laroprovstat/rosuvastatin 4

  • DrugRosuvastatin 1

    daily oral dose of rosuvastatin 1

  • DrugRosuvastatin 2

    daily oral dose of rosuvastatin 2

  • DrugRosuvastatin 3

    daily oral dose of rosuvastatin 3

  • DrugRosuvastatin 4

    daily oral dose of rosuvastatin 4

  • DrugPlacebo to match Rosuvastatin

    daily oral dose of placebo to match rosuvastatin

06

What researchers measure

Primary outcomes

  1. Relative change in LDL-C at 8 weeks

    To compare the effect of treatment with laroprovstat/rosuvastatin versus rosuvastatin on LDL-C at 8 weeks

    Time frame: 8 weeks

Secondary outcomes

  1. Relative change in Apo B at 8 weeks

    To compare the effect of treatment with laroprovstat/rosuvastatin versus rosuvastatin on Apo B at 8 weeks

    Time frame: 8 weeks

  2. Relative change in non-HDL-C at 8 weeks

    To compare the effect of treatment with laroprovstat/rosuvastatin versus rosuvastatin on non-HDL-C at 8 weeks

    Time frame: 8 weeks

  3. Relative change in total cholesterol at 8 weeks

    To compare the effect of treatment with laroprovstat/rosuvastatin versus rosuvastatin on total cholesterol at 8 weeks

    Time frame: 8 weeks

07

Study locations

16 of 45 sites recruiting
  • Research Site
    Sun City West, Arizona 85375, United States
    Recruiting
  • Research Site
    Gardena, California 90247, United States
    Not yet recruiting
  • Research Site
    Lomita, California 90717, United States
    Not yet recruiting
  • Research Site
    Pomona, California 91768, United States
    Recruiting
  • Research Site
    Sacramento, California 95821, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32216, United States
    Not yet recruiting
  • Research Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Research Site
    Orlando, Florida 32807, United States
    Not yet recruiting
  • Research Site
    Pembroke Pines, Florida 33029, United States
    Not yet recruiting
  • Research Site
    Conyers, Georgia 30094, United States
    Recruiting
  • Research Site
    Decatur, Georgia 30030, United States
    Recruiting
  • Research Site
    Peachtree Corners, Georgia 30092, United States
    Not yet recruiting
  • Research Site
    Evansville, Indiana 47714, United States
    Not yet recruiting
  • Research Site
    Indianapolis, Indiana 46260, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Zachary, Louisiana 70791, United States
    Not yet recruiting
  • Research Site
    Beltsville, Maryland 20705, United States
    Recruiting
  • Research Site
    Rocky Mount, North Carolina 27804, United States
    Not yet recruiting
  • Research Site
    Statesville, North Carolina 28625, United States
    Not yet recruiting
  • Research Site
    Wilmington, North Carolina 28401, United States
    Not yet recruiting
  • Research Site
    Fargo, North Dakota 58104, United States
    Not yet recruiting
  • Research Site
    Anderson, South Carolina 29621, United States
    Not yet recruiting
  • Research Site
    Bristol, Tennessee 37620, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77002, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77040, United States
    Recruiting
  • Research Site
    Mesquite, Texas 75149, United States
    Recruiting
  • Research Site
    Sugar Land, Texas 77478, United States
    Recruiting
  • Research Site
    Burwood, 2134, Australia
    Not yet recruiting
  • Research Site
    Hope Island, 4212, Australia
    Recruiting
  • Research Site
    Hoppers Crossing, 3029, Australia
    Not yet recruiting
  • Research Site
    Woolloongabba, 4102, Australia
    Recruiting
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Guelph, Ontario N1H 1B1, Canada
    Recruiting
  • Research Site
    Mississauga, Ontario L5K2L3, Canada
    Recruiting
  • Research Site
    North York, Ontario M9N 1W4, Canada
    Recruiting
  • Research Site
    Stoney Creek, Ontario L8J 3W2, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M6G 1M2, Canada
    Recruiting
  • Research Site
    Berlin, 10117, Germany
    Not yet recruiting
  • Research Site
    Essen, 45355, Germany
    Not yet recruiting
  • Research Site
    Frankfurt, 60596, Germany
    Not yet recruiting
  • Research Site
    Freiburg im Breisgau, 79106, Germany
    Not yet recruiting
  • Research Site
    Hanover, 30159, Germany
    Not yet recruiting
  • Research Site
    Kaiserslautern, 67655, Germany
    Not yet recruiting
  • Research Site
    Leipzig, 04103, Germany
    Not yet recruiting
  • Research Site
    Munich, 80809, Germany
    Not yet recruiting
  • Research Site
    Nuremberg, 90402, Germany
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 8 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 1, 2026
StartActual
Sep 10, 2026
Primary completionEst.
May 28, 2027
CompletionEst.
May 28, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
45 sites added — first sites in Australia, Canada, Germany and United States
Show 45 added (26 United States, 9 Germany, 6 Canada, 4 Australia)
  • Research Site · Sun City West, United States
  • Research Site · Gardena, United States
  • Research Site · Lomita, United States
  • Research Site · Pomona, United States
  • Research Site · Sacramento, United States
  • Research Site · Jacksonville, United States
  • Research Site · Miami Lakes, United States
  • Research Site · Orlando, United States
  • Research Site · Pembroke Pines, United States
  • Research Site · Conyers, United States
  • Research Site · Decatur, United States
  • Research Site · Peachtree Corners, United States
  • Research Site · Evansville, United States
  • Research Site · Indianapolis, United States
  • Research Site · Zachary, United States
  • Research Site · Beltsville, United States
  • Research Site · Rocky Mount, United States
  • Research Site · Statesville, United States
  • Research Site · Wilmington, United States
  • Research Site · Fargo, United States
  • Research Site · Anderson, United States
  • Research Site · Bristol, United States
  • Research Site · Houston, United States
  • Research Site · Houston, United States
  • Research Site · Mesquite, United States
  • Research Site · Sugar Land, United States
  • Research Site · Burwood, Australia
  • Research Site · Hope Island, Australia
  • Research Site · Hoppers Crossing, Australia
  • Research Site · Woolloongabba, Australia
  • …and 15 more on the registry record
Oct 5, 2026
Start date
Sep 15, 2026→Sep 10, 2026 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    45 sites added — first sites in Australia, Canada, Germany and United States
    Show 45 added (26 United States, 9 Germany, 6 Canada, 4 Australia)
    • Research Site · Sun City West, United States
    • Research Site · Gardena, United States
    • Research Site · Lomita, United States
    • Research Site · Pomona, United States
    • Research Site · Sacramento, United States
    • Research Site · Jacksonville, United States
    • Research Site · Miami Lakes, United States
    • Research Site · Orlando, United States
    • Research Site · Pembroke Pines, United States
    • Research Site · Conyers, United States
    • Research Site · Decatur, United States
    • Research Site · Peachtree Corners, United States
    • Research Site · Evansville, United States
    • Research Site · Indianapolis, United States
    • Research Site · Zachary, United States
    • Research Site · Beltsville, United States
    • Research Site · Rocky Mount, United States
    • Research Site · Statesville, United States
    • Research Site · Wilmington, United States
    • Research Site · Fargo, United States
    • Research Site · Anderson, United States
    • Research Site · Bristol, United States
    • Research Site · Houston, United States
    • Research Site · Houston, United States
    • Research Site · Mesquite, United States
    • Research Site · Sugar Land, United States
    • Research Site · Burwood, Australia
    • Research Site · Hope Island, Australia
    • Research Site · Hoppers Crossing, Australia
    • Research Site · Woolloongabba, Australia
    • …and 15 more on the registry record
    Start date Sep 15, 2026→Sep 10, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07619118
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Sep 10, 2026
Primary completion
May 28, 2027 (estimated)
Completion
May 28, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion